Data from cancer genomics has indicated a correlation between heightened levels of glycogen synthase 1 and 2 (GYS1/2) or glycogen branching enzyme 1 with unfavorable outcomes in AML patients. The gene discussed is GYS1; the disease is acute myeloid leukemia.